Saquinavir/low-dose ritonavir: its use in HIV infection
Johnson, M.; Peters, B.
Aids Reviews 5(1): 44-51
2003
ISSN/ISBN: 1139-6121 PMID: 12875107 Document Number: 559618
Exposure to saquinavir can be increased considerably by pharmacokinetic enhancement with ritonavir, without having a substantial impact on tolerability. Clinical trials indicate that both once-daily and twice-daily saquinavir/ritonavir treatment regimens, generally at dosages of 1,600 mg/100 mg once daily and 1,000 mg/100 mg twice daily, provide potent and sustained viral suppression and are well tolerated. In addition, data suggest that "double-boosting" strategies, including the combination of saquinavir with lopinavir/ritonavir, provide valuable treatment options in the salvage setting.
Document emailed within 1 workday
Related Documents
Cameron, D.W.; Japour, A.J.; Xu, Y.; Hsu, A.; Mellors, J.; Farthing, C.; Cohen, C.; Poretz, D.; Markowitz, M.; Follansbee, S.; Angel, J.B.; McMahon, D.; Ho, D.; Devanarayan, V.; Rode, R.; Salgo, M.; Kempf, D.J.; Granneman, R.; Leonard, J.M.; Sun, E. 1999: Ritonavir and saquinavir combination therapy for the treatment of HIV infection Aids 13(2): 213-224Soria, A.; Gianotti, N.; Cernuschi, M.; Lazzarin, A. 2004: Once-daily saquinavir and ritonavir in treatment-experienced HIV-1-infected individuals New Microbiologica 27(1): 11-15
Brites; Alcântara; Mosqueira; Gimbo; Pedroso; Pedral-Sampaio 1999: Safety and Efficacy of Reduced Doses of Ritonavir (RTV) Plus Saquinavir (SQV) in the Treatment of AIDS Patients in Brazil Brazilian Journal of Infectious Diseases: An Official Publication of the Brazilian Society of Infectious Diseases 3(3): 91-96
Ananworanich, J.; Hirschel, B.; Sirivichayakul, S.; Ubolyam, S.; Jupimai, T.; Prasithsirikul, W.; Chetchotisakd, P.; Kiertiburanakul, S.; Munsakul, W.; Raksakulkarn, P.; Tansuphasawadikul, S.; Schutz, M.; Snowden, W.; Ruxrungtham, K. 2006: Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir Antiviral Therapy 11(5): 631-635
Lamotte, C.; Landman, R.; Peytavin, G.; Mentre, F.; Gerbe, J.; Brun-Vezinet, F.ço.; Boue, F.ço.; Spiridon, G.; Valantin, M.-A.; Michelet, C.; Farinotti, R.; Yeni, P. 2004: Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study) Antiviral Therapy 9(2): 247-256
Marcelin, A.-G.; Flandre, P.; de Mendoza, C.; Roquebert, B.; Peytavin, G.; Valer, L.; Wirden, M.; Abbas, S.; Katlama, C.; Soriano, V.; Calvez, V. 2007: Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients Antiviral Therapy 12(2): 247-252
Patel, A.K.; Patel, K.K.; Naik, E.; Jingyi Duan; Ranjan, R.; Patel, J.K.; Salihu, H.M. 2011: Comparison of the Effectiveness of Low-Dose Indinavir/Ritonavir (IDV/r)- versus Atazanavir/Ritonavir (ATV/r)-Based Generic Antiretroviral Therapy in NNRTI-Experienced HIV-1-Infected Patients in India Journal of the International Association of Physicians in Aids Care 10(2): 111-118
Manosuthi, W.; Sungkanuparph, S.; Ruxrungtham, K.; Prasithsirikul, W.; Athichathanabadi, C.; Tantisiriwat, W.; Bowonwatanuwong, C.; Chumpathat, N.; Chaovavanich, A. 2008: Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir Journal of Acquired Immune Deficiency Syndromes 47(1): 127-129
Kuschak, D.; Mauss, S.; Schmutz, G.; Gantke, B. 2001: Simultaneous Determination of the New HIV Protease Inhibitor Lopinavir (ABT 378) and of Indinavir (1), Amprenavir, Saquinavir, Ritonavir (ABT 538) (2) and Nelfinavir (3) in Human Plasma by Gradient HPLC Clinical Laboratory 47(9-10): 471-477
Moyle, G. 1997: Saquinavir in the management of HIV infection British Journal of Hospital Medicine 57(11): 560-564
Waters, L.J.; Moyle, G.; Bonora, S.; D'Avolio, A.; Else, L.; Mandalia, S.; Pozniak, A.; Nelson, M.; Gazzard, B.; Back, D.; Boffito, M. 2007: Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients Antiviral Therapy 12(5): 825-830
1996: Ritonavir for advanced HIV infection American Family Physician 54(1): 372 374
Chong, K.T.; Pagano, P.J. 1997: In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates Antimicrobial Agents and ChemoTherapy 41(11): 2367-2373
Sunpath, H.; Winternheimer, P.; Cohen, S.; Tennant, I.; Chelin, N.; Gandhi, R.T.; Murphy, R.A. 2014: Double-dose lopinavir-ritonavir in combination with rifampicin-based anti-tuberculosis treatment in South Africa International Journal of Tuberculosis and Lung Disease: the Official Journal of the International Union Against Tuberculosis and Lung Disease 18(6): 689-693
Wasmuth, J.-C.; la Porte, C.J.L.; Schneider, K.; Burger, D.M.; Rockstroh, J.K. 2004: Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR) Antiviral Therapy 9(2): 213-220
Galegov, G.A. 2007: Protease inhibitor Kaletra (Lopinavir/Ritonavir): significance and role in antiretroviral therapy of HIV infection and AIDS Antibiotiki i Khimioterapiia 52(1-2): 42-45
Wheat, L.J.; Farthing, C.; Cohen, C.; Pierone, G.; Lalezari, J.; Pilson, R.S.; Siemon-Hryczyk, P. 2002: Efficacy and safety of twice-daily versus three-times daily saquinavir soft gelatin capsules as part of triple combination therapy for HIV-1 infection Antiviral Therapy 7(3): 199-209
Koudriakova, T.; Iatsimirskaia, E.; Utkin, I.; Gangl, E.; Vouros, P.; Storozhuk, E.; Orza, D.; Marinina, J.; Gerber, N. 1998: Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir Drug Metabolism and Disposition: the Biological Fate of Chemicals 26(6): 552-561
Mathez, D.; Bagnarelli, P.; Gorin, I.; Katlama, C.; Pialoux, G.; Saimot, G.; Tubiana, P.; De Truchis, P.; Chauvin, J.P.; Mills, R.; Rode, R.; Clementi, M.; Leibowitch, J. 1997: Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy Antiviral Therapy 2(3): 175-183
Colpaert, F.C.; Janssen, P.A. 1982: Factors regulating drug cue sensitivity: the effects of dose ratio and absolute dose level in the case of fentanyl dose-dose discrimination Archives Internationales de Pharmacodynamie et de Therapie 258(2): 283-299